Compare Quest Diagnostics Inc (DGX) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs MasterCard Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while MasterCard Inc trades at $537.96 (market cap $475.39B). The key difference: MasterCard Inc is far larger — about 20.9× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | MA | |
|---|---|---|
Market Cap | $22.80B | $475.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $598.96 |
52-Week Low | $166.42 | $471.55 |
Enterprise Value | $28.82B | $486.13B |
Dividend Yield | 1.67% | 0.65% |
Volume | — | 4,635,698 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Mastercard (MA) trades at $537.70, up 2.08% today, with a bullish technical outlook and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.60 exceeding the $4.41 estimate. Revenue grew to $32.79B in 2025, and net income margin remains robust at 45.88%. Analysts maintain a strong buy consensus, with a price target of $634.27, indicating ~18% upside. Recent news highlights institutional accumulation and AI-driven payment innovations.
The outlook for MA is positive, driven by earnings momentum and strategic expansion into digital payments. Key risks include competitive disruption from stablecoins and regulatory scrutiny. With high profitability and institutional support, the stock presents a growth opportunity, though investors should monitor payment industry evolution and macroeconomic factors affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
